Humacyte Founder Laura Niklason, M.D., Ph.D. to Present at the American Heart Association Scientific Sessions

Go Back

November 2, 2015

RESEARCH TRIANGLE PARK, N.C. — Humacyte, an innovator in biotechnology and regenerative medicine, announced today that Company founder, Laura Niklason, M.D., Ph.D., a world leader in tissue engineering and cellular therapies, will address the American Heart Association (AHA) Scientific Sessions. The conference, one of the leading cardiovascular meetings in the country, will be held from November 7-11 in Orlando, Fla.

Dr. Niklason will deliver a presentation titled “Bioengineered Arteries for Peripheral Bypass: Early Clinical Experience” on Monday, November 9.

Dr. Niklason’s work in regenerative medicine includes the development of Humacyte’s HUMACYL™, an investigational human acellular vessel (HAV), which has the potential to provide vascular access for patients with End Stage Renal Disease who require hemodialysis. The technology also has the potential to address a range of vascular and non-vascular diseases, such as Coronary Artery Bypass, Replacement Trachea and Esophagus, and bypass for Peripheral Arterial Disease.

“Following decades of work in the regenerative medicine space, we now see great promise for alternative tissue and vessel options for a range of applications,” said Dr. Niklason. “AHA Scientific Sessions offer a valuable platform to highlight the potential extension of the HAV technology for peripheral arterial disease, and I look forward to addressing my colleagues at the conference.”

Dr. Niklason is a Professor of Biomedical Engineering and Anesthesiology at Yale University, where she also has a vigorous scientific laboratory, and works to expand novel cellular therapies. Her research focuses primarily on regenerative strategies for cardiovascular and lung tissues, and the impact of biomechanical and biochemical signals of tissue differentiation and development. Dr. Niklason’s career also includes time spent at Duke University where she taught biomedical engineering, anesthesia and surgery. In October, Dr. Niklason was elected to National Academy of Medicine, a prestigious organization and one of the highest honors in the field of medicine. She also speaks globally at conferences on her research, has authored scores of peer-reviewed articles, and has been bestowed with numerous awards for scientific excellence.

For more on the Scientific Sessions, visit the AHA website.

About Humacyte

Humacyte, Inc., a privately held company founded in 2004, is a medical research, discovery and development company with clinical and pre-clinical stage investigational products. Humacyte is primarily focused on developing and commercializing a proprietary novel technology based on human tissue-based products for key applications in regenerative medicine and vascular surgery. The company uses its innovative, proprietary platform technology to engineer human, extracellular matrix-based tissues that can be shaped into tubes, sheets, or particulate conformations, with properties similar to native tissues. These are being developed for potential use in many specific applications, with the goal to significantly improve treatment outcomes for many patients, including those with vascular disease and those requiring hemodialysis. The company’s proprietary technologies are designed to create off-the-shelf products that, once approved, can be utilized in any patient. The company web site is

All statements, other than statements of historical fact, included in this announcement are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “will”, “anticipate”, “expect”, “believe”, “intend” and “should” or the negative of these terms or other comparable terminology. These statements relate to future events or Humacyte’s clinical development programs, reflect management’s current beliefs and expectations and involve known and unknown risks, uncertainties and other factors that may cause Humacyte’s actual results, performance or achievements to be materially different. Except as required by law, Humacyte assumes no obligation to update these forward-looking statements.